NurExone Biologic (FRA:J90) Construction In Progress: €0.00 Mil (As of Mar. 2026)


FRA:J90 NurExone Biologic Inc FRA:J90
36 GF Score
Price €0.32
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Construction In Progress?

NurExone Biologic FRA:J90 +8.16% 36 Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:J90 with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

NurExone Biologic Construction In Progress Historical Data

* Premium members only.

The historical data trend for NurExone Biologic's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NurExone Biologic Construction In Progress Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
0.00 0.00 0.00 0.00 0.00

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:J90
36GF Score
NurExone Biologic Inc FRA:J90
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
NurExone Biologic (FRA:J90) has a Construction In Progress of €0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on NurExone Biologic and its competitors.
Is NurExone Biologic's Construction In Progress too high?
NurExone Biologic's current Construction In Progress is €0.00 Mil. Overall, NurExone Biologic has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does NurExone Biologic's Construction In Progress compare to VRTX and REGN?
NurExone Biologic's Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on NurExone Biologic and its competitors. NurExone Biologic's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NurExone Biologic stock overvalued right now?
NurExone Biologic (FRA:J90) has a current Construction In Progress of €0.00 Mil. The current Construction In Progress is €0.00 Mil. NurExone Biologic's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For NurExone Biologic (FRA:J90), the current Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
36GF Score

Get the complete analysis for FRA:J90

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.32
Price